Opinion|Videos|October 24, 2024
Impact of Comorbidities on IPF Management
Author(s)Toby Maher, MD, PhD
Key Takeaways
- Comorbidities can obscure IPF symptoms, leading to diagnostic delays or misdiagnoses, complicating the clinical presentation.
- Comprehensive evaluation is crucial to tailor treatment plans addressing both IPF and comorbidities effectively.
Toby Maher, MD, PhD, discusses how comorbidities complicate the diagnosis and management of idiopathic pulmonary fibrosis (IPF) and influence treatment decisions, highlighting the need for a comprehensive approach in patient care.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How do comorbidities affect diagnosis and management of IPF? In what ways do comorbidities affect treatment decisions?
Advertisement
Related to this article
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
3
Study Finds Possible Deep Endometriosis in 7% of Postmenopausal Women
4
US Measles Outbreaks Cost Nearly $83 Million in 2026
5